Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and
response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging …

Cytochrome P450 2B6 (CYP2B6) belongs to the minor drug metabolizing P450s in human
liver. Expression is highly variable both between individuals and within individuals, owing to …

Multiple candidate gene-association studies of non-HLA single-nucleotide polymorphisms
(SNPs) and outcomes after blood or marrow transplant (BMT) have been conducted. We …

Purpose Genetic variation in the activation of the prodrug cyclophosphamide (CP) by
cytochrome P450 (CYP) enzymes has been shown to influence outcomes. However, CYP …

Cyclophosphamide is an alkylating agent used in the treatment of solid and haematological
malignancies and as an immunosuppressive agent. As a prodrug, it is dependent on …

The activity of the autoimmune mechanism underlying type 1 diabetes mellitus (T1DM) can
be suppressed when immunoablation and autologous hematopoietic stem cell …

Fludarabine plus cyclophosphamide (FC) is the chemotherapy backbone of modern chronic
lymphocytic leukemia (CLL) treatment. CYP2B6 is a polymorphic cytochrome P450 isoform …

Cytochrome P450 enzymes (CYPs) and flavin-containing monooxygenases (FMOs) likely
have a role in the oxidation of intermediate metabolites of busulfan (Bu). In vitro studies to …

Though current knowledge of pharmacogenetic factors relevant to drug metabolism is fairly
comprehensive and this should facilitate translation to the clinic, there are a number of gaps …

To investigate the impact of cytochrome P450 (CYP) genetic polymorphisms CYP2B6,
CYP2C19, and CYP3A5 on mRNA expression, cyclophosphamide/4 …